Literature DB >> 8126451

Cis- and trans-regulation of feline immunodeficiency virus: identification of functional binding sites in the long terminal repeat.

F J Thompson1, J Elder, J C Neil.   

Abstract

Nuclear protein binding sites in the long terminal repeat (LTR) of feline immunodeficiency virus (FIV) were identified by the method of DNase I footprinting. Using nuclear protein extracts from a feline T lymphoma cell line, several discrete footprints were generated upstream of the transcriptional initiation site (-50 to -150). The specificity of protein binding was examined by competition with oligonucleotides representing consensus DNA binding sites for known transcription factors. Binding to AP-1 (-124) and ATF (-58) motifs was observed, with cross-competition between these sites. A strong footprint signal was also detected over a tandemly repeated C/EBP motif (-94, -86) and an adjacent weaker footprint was found to be specific for an NF1 motif (-72/-63). The effect on FIV LTR promoter activity of progressively deleting these nuclear factor binding sites was examined by linking LTR deletion mutants to the chloramphenicol acetyltransferase (CAT) gene. Deletion of the AP-1 site caused a 10- to 25-fold loss of CAT activity whereas deletion past the ATF site reduced activity virtually to background levels. The effects of deleting the C/EBP and NF1 sites were less marked and varied according to cell type. Transactivation of the LTR was assayed using constructs linked to a CAT reporter gene. The full-length FIV LTR was not significantly trans-activated. However, the expression of a deleted LTR construct lacking the AP-4/AP-1 site but retaining C/EBP and ATF sites was partially restored by co-infection with FIV or by co-transfection with an infectious molecular clone of FIV (FIV-PPR). These results show that host transcription factors responsive to cellular activation have a major role in regulating FIV expression, and suggest that virus-coded trans-activators acting through U3 may play a role in some cellular environments.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8126451     DOI: 10.1099/0022-1317-75-3-545

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  Optimization of feline immunodeficiency virus vectors for RNA interference.

Authors:  Scott Q Harper; Patrick D Staber; Christine R Beck; Sarah K Fineberg; Colleen Stein; Dalyz Ochoa; Beverly L Davidson
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Evolution of the long terminal repeat and accessory genes of feline immunodeficiency virus genomes from naturally infected cougars.

Authors:  Mary Poss; Howard Ross
Journal:  Virology       Date:  2007-09-29       Impact factor: 3.616

3.  Preferential feline immunodeficiency virus (FIV) infection of CD4+ CD25+ T-regulatory cells correlates both with surface expression of CXCR4 and activation of FIV long terminal repeat binding cellular transcriptional factors.

Authors:  Anjali Joshi; Himanshu Garg; Mary B Tompkins; Wayne A Tompkins
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Construction and in vitro characterization of attenuated feline immunodeficiency virus long terminal repeat mutant viruses.

Authors:  L Bigornia; K M Lockridge; E E Sparger
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Phylogenetic analysis of the long terminal repeat of feline immunodeficiency viruses from Japan, Argentina and Australia.

Authors:  H Yamada; T Miyazawa; K Tomonaga; Y Kawaguchi; K Maeda; M C Castellano; C Kai; Y Tohya; T Mikami
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

6.  Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators.

Authors:  Udayan Chatterji; Aymeric de Parseval; John H Elder
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 7.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

8.  Peripheral immunophenotype and viral promoter variants during the asymptomatic phase of feline immunodeficiency virus infection.

Authors:  B Murphy; C Hillman; S McDonnel
Journal:  Virus Res       Date:  2013-11-28       Impact factor: 3.303

9.  Demonstration that orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial rev activity.

Authors:  A de Parseval; J H Elder
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  Feline immunodeficiency virus ORF-Ais required for virus particle formation and virus infectivity.

Authors:  Malou C Gemeniano; Earl T Sawai; Christian M Leutenegger; Ellen E Sparger
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.